5913 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1735)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2526)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)

More Groups

People
  1. Marc Ladanyi (1326)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (119)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (262)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (757)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5913)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary safety results of the open-label phase of a 2-part phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic cell transplantation
    Meeting Abstract

    Ponce, D. M.; Kosuri, S.; Khera, N.; Defilipp, Z.; Lichter, D. I.; Peled, J. U.; van den Brink, M. R. M.; Brady, K.; Puhl, M. D.; Glick, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and-7
    Meeting Abstract

    Kunimoto, H.; Miura, A.; Sagisaka, M.; Ito, M.; Honma, D.; Tsutsumi, S.; Sakuma, T.; Ohashi, T.; Teranaka, H.; Ikeda, J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A pro-inflammatory gene signature characterizes a better risk aged AML patient group in ECOG-ACRIN Cancer Research Group's clinical trial E3999
    Meeting Abstract

    Neelamraju, Y.; Rapaport, F.; Gandara, J. A.; Dunham, N.; Fan, H.; Lee, T.; Prajapati, S.; Sheridan, C.; Wang, L.; Cripe, L. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Use of a tissue-targeting recombinant human interleukin-22 fusion molecule (F-652) for the treatment of advanced refractory lower GI acute GVHD
    Meeting Abstract

    Satta, T.; Papadopoulos, E. B.; Gyurkocza, B.; Susman, P.; Singh, A.; Calafiore, M.; Giralt, S. A.; Perales, M. A.; Chen, J.; Li, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Infectious complications in patients with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) treated with the anti-CD20xCD3 bispecific antibody (BsAb) mosunetuzumab
    Meeting Abstract

    Shahid, Z.; Okwali, M.; Joseph, A.; Seo, S. K.; Lue, J. K.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of limited stage high grade B-cell lymphoma with MYC/BCL2 and/or BCL6 rearrangements: A single center experience
    Meeting Abstract

    Lue, J. K.; Luttwak, E.; Caron, P.; Boardman, A. P.; David, K. A.; Rivas-Delgado, A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save